2. UroToday Home
  3. Video Lectures

Journal Clubs Videos

Study of PSA Testing Perceptions Among Black Patients and Their Physicians, Journal Club - Rashid Sayyid & Zachary Klaassen
The RAMPP Trial: The Role of Radical Prostatectomy in Oligometastatic Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Phase III EV-302 Trial Reports Outcomes with 2.5 Years of Follow-Up, Journal Club - Rashid Sayyid & Zachary Klaassen
Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen
VIOLET Trial of Terbium-161 PSMA-I&T in mCRPC Patients, Journal Club - Rashid Sayyid & Zachary Klaassen
Persistent PSA After Prostatectomy: Timing and Mortality Risk Implications, Journal Club - Rashid Sayyid & Zachary Klaassen
Sasanlimab Plus BCG Improves Event-Free Survival in High-Risk NMIBC: First Interim Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
PEACE-3 Trial: Enzalutamide Plus Radium-223 Improves Survival in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen
Radium-223 Plus Enzalutamide Improves Survival in mCRPC: PEACE-3 Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
UpFrontPSMA Trial Results: Lutetium-177 PSMA-617 in Hormone-Sensitive Prostate Cancer, Journal Club - Phillip Koo & Zachary Klaassen
ARANOTE Trial Implications for Metastatic Prostate Cancer Management, Journal Club - Rashid Sayyid & Zachary Klaassen
Cardiovascular Risks of ARSIs in Prostate Cancer: Meta-Analysis Findings, Journal Club - Rashid Sayyid & Zachary Klaassen
2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
PI-CAI Challenge: AI vs Radiologists in Prostate Cancer MRI Detection, Journal Club - Rashid Sayyid & Zachary Klaassen
NCCN 2024 Prostate Cancer Guidelines Update: PARP Inhibitors in Focus - Rashid Sayyid & Zachary Klaassen
Evaluating a Sequential Screening Approach for Prostate Cancer Using PSA, Kallikrein Panel, and MRI in the ProScreen Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
ARASENS Subgroup Analysis on Triplet Therapy Improves Outcomes for Black Patients with mHSPC, Journal Club - Rashid Sayyid & Zachary Klaassen
ProtecT Trial 15-Year Data Shows Low Prostate Cancer Mortality Across Therapies for Localized Disease, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
Discussion Between Expert Clinicians and Patients on the ProtecT Trial, A Journal Club for Patients with Prostate Cancer - Matthew Cooperberg
Consensus Recommendations to Optimize Low and Intermediate-Risk Bladder Cancer Studies, Journal Club - Rashid Sayyid & Zachary Klaassen
International Panel Defines Endpoints and Control Arms for Trials in Locally Advanced and Metastatic Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen
Multi-Disciplinary Panel Defines Clinical Trial Framework for Muscle-Invasive Bladder Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Reviewing Evidence on Bone Health and Future Directions in Updated Prostate Cancer Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen
Guideline Revisions Seek to Optimize Detection and Management of Recurrent Prostate Cancer Without Evident Metastasis, Journal Club - Rashid Sayyid & Zachary Klaassen
From Epidemiology to Surgery: A Comprehensive Look at AUA's BPH Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen
Review of Medical Therapy Options in Updated AUA Guidelines for BPH Management, Journal Club - Rashid Sayyid & Zachary Klaassen
AUA's Surgical Guidelines for BPH: From Patient Assessment to Procedure Selection, Journal Club - Rashid Sayyid & Zachary Klaassen
Examining Expert Recommendations Seeking to Update Outdated Standards in BPH Evaluation and Management, Journal Club - Rashid Sayyid & Zachary Klaassen
Epidemiological Trends and Treatment Innovations in Advanced Prostate Cancer: An In-Depth Analysis of the AUA's Amended 2023 Guidelines, Journal Club - Rashid Sayyid & Zachary Klaassen
Triple-Drug Therapies Usher in Sea Change for Men With High-Risk Prostate Cancer - Rashid Sayyid & Zachary Klaassen
Expert Guidelines Detail Optimal Sequencing of Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
AUA Guidelines Provide Roadmap for Assessing Disease Burden and Personalizing Systemic Therapies in Metastatic Hormone Sensitive Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Risk Stratification and Pre-Surgical Assessments According to AUA Guidelines for Upper Tract Urothelial Carcinoma, Journal Club - Rashid Sayyid & Zachary Klaassen
Unpacking the AUA Guidelines: Neoadjuvant Chemotherapy and Surveillance in Non-Metastatic Upper Tract Urothelial Carcinoma, Journal Club - Rashid Sayyid & Zachary Klaassen
Exploring Kidney-Sparing Management: An In-Depth Look at Tumor Ablation Techniques, AUA Guidelines, and the Role of Jelmyto in Upper Tract Urothelial Carcinoma, Journal Club - Rashid Sayyid & Zachary Klaassen
KEYNOTE-B61 Trial Reveals Promising Results for Pembrolizumab and Lenvatinib Combination in Advanced Non-Clear Cell Renal Cell Carcinoma, Journal Club - Rashid Sayyid & Zachary Klaassen
How Race Influences Trust in Online Prostate Cancer Content, Journal Club - Rashid Sayyid & Zachary Klaassen
Agent Orange Exposure and Bladder Cancer Risk: A Comprehensive Study Among US Veterans, Journal Club - Rashid Sayyid & Zachary Klaassen
A New Approach to Bladder Cancer: The ATLAS Trial's Exploration of UGN-102 and TURBT, Journal Club - Rashid Sayyid & Zachary Klaassen
A Comprehensive Look at Genomic Classifier Performance in Intermediate Risk Prostate Cancer: Insights from the NRG Oncology/RTOG 01-26 Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
A Head-to-Head Comparison: 68 Gallium-NODAGA-JR11 and 68 Gallium-DOTATATE PET/CT in Neuroendocrine Tumors, Journal Club - Rashid Sayyid & Zachary Klaassen
TRAVERSE Trial Insights: A Comprehensive Look at Testosterone Replacement Therapy and Cardiovascular Safety, Journal Club - Rashid Sayyid & Zachary Klaassen
The ACDC-RP Phase II Trial: Understanding the Impact on High-Risk Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
A Leap Forward in Prostate Cancer Care: AI Model Guides Individualized Hormone Therapy Decisions, Journal Club - Rashid Sayyid & Zachary Klaassen
Transcriptomic and Clinical Heterogeneity in Metastatic Castration-Sensitive Prostate Cancer: Unraveling the Molecular Landscape, Journal Club - Rashid Sayyid & Zachary Klaassen
AR and PI3K Genomic Profiling in Lutetium-177-PSMA Treatment: A Pathway to Identifying Poor Responders, Journal Club - Rashid Sayyid & Zachary Klaassen
Tailoring Treatment Strategies: How a Nomogram Guides PSMA-PET Salvage Radiotherapy, Journal Club - Rashid Sayyid & Zachary Klaassen
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare, Journal Club - Rashid Sayyid & Zachary Klaassen
Oligometastatic Prostate Cancer: Unraveling Differences Between Imaging Techniques, Journal Club - Rashid Sayyid & Zachary Klaassen
No Benefit from Checkpoint Inhibitor Rechallenge: Key Findings from CONTACT-03 Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
The Future of Kidney Cancer Treatment: COSMIC-313 Trial Breakdown, Journal Club - Rashid Sayyid & Zachary Klaassen
Assessing Reader Variability in PSMA-PET/CT Scan Interpretation: A Substudy of the VISION Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Improving mCRPC Outcomes: VISION Study Highlights Lu-PSMA-617 Impact on Survival and Quality of Life, Journal Club - Rashid Sayyid & Zachary Klaassen
How the TALAPRO-2 Study is Redefining First-line Treatment for Metastatic Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Exploring the Role of ATM and BRCA2 Mutations in Metastatic Prostate Cancer Outcomes, Journal Club - Rashid Sayyid & Zachary Klaassen
Filling the Gap: Creating a Specialized PRO Measure for Radionuclide Therapy in Prostate Cancer, Journal Club - Zachary Klaassen & Rashid Sayyid
Decoding Survival: The Role of Bone Biomarkers in Hormone-Sensitive Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
The Push for PSMA-PET: Evaluating its Role in Prostate Cancer Diagnosis, Journal Club - Rashid Sayyid & Zachary Klaassen
The Impact of MDT on Intermittent Hormone Therapy: Insights from the EXTEND Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Ga-PSMA PET for Evaluation of Response to Chemotherapy for Metastatic Prostate Cancer, Journal Club - Rashid Sayyid & Zachary Klaassen
Evaluating Outcomes of Enzalutamide and Abiraterone Co-administration: Insights from the ALLIANCE Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Two-Year Follow-Up: Avelumab Improves Survival in Advanced Urothelial Carcinoma, Journal Club - Rashid Sayyid & Zachary Klaassen
Comparative Analysis of Radical Cystectomy and Trimodality Therapy for Muscle-Invasive Bladder Cancer, Journal Club – Rashid Sayyid & Zachary Klaassen
Examining Survival Rates in Prostate Cancer: Exploring the STAMPEDE Platform, Journal Club - Rashid Sayyid & Zachary Klaassen
Racial Differences in Prostate Cancer Germline Genetic Testing, Journal Club - Rashid Sayyid & Zachary Klaassen
Exploring PSMA PET-Based Response's Prognostic Role in Prostate Cancer Treatment, Journal Club - Rashid Sayyid & Zachary Klaassen
MARCAP Meta-Analysis of Surrogate Endpoints for Overall Survival, Journal Club - Rashid Sayyid & Zachary Klaassen
Breakthrough Insights from the MAGNITUDE Study, Journal Club - Rashid Sayyid & Zachary Klaassen
Crucial Insights from ENZAMET, Journal Club - Zachary Klaassen & Rashid Sayyid
Functional and Quality-of-Life Impacts of Prostatectomy, Radiotherapy, and Active Monitoring: Patient-Reported Outcomes from the ProtecT Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
Fifteen-Year Outcomes of Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer: Trade-offs between Benefits and Harms of Treatment Options from the ProtecT Trial, Journal Club - Rashid Sayyid & Zachary Klaassen
TP53 Variants and Prostate Cancer Risk Journal Club - Zachary Klaassen
A Patient-Choice Study: Pretest Genetic Education Video vs Genetic Counseling for Men Considering Prostate Cancer Germline Testing Journal Club – Zachary Klaassen
The UK Genetic Prostate Cancer Study, Family History of Prostate Cancer and Survival Outcomes Journal Club - Zachary Klaassen
Changes in Rates of PSA Testing After Revisions in the USPSTF Guideline on Prostate Cancer Screening Journal Club - Zachary Klaassen
mpMRI What Urologists Need to Know: Targeted Biopsy - Zachary Klaassen
Bone Mineral Density Among Older Men Receiving ADT to Treat Localized or Regional Prostate Cancer, Journal Club - Zachary Klaassen
Management of Urinary Toxicity from Prostate Radiotherapy Journal Club - Zachary Klaassen
NCCN 2023 Updates and Mini-Section on Quality-of-Life and Shared-Decision Making, Journal Club - Christopher J.D. Wallis & Zachary Klaassen
Stockholm3 Tests to Inform Risk Stratification before MRI and Targeted Biopsies in the Prostate Cancer Screening Setting, Journal Club - Zachary Klaassen
Genetic Scores as an Objective Measure of Prostate Cancer Risk To Inform Screening Decisions, a Retrospective Analysis of the Million Veteran Program, Journal Club - Zachary Klaassen
MRI-Guided vs CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer, The MIRAGE Randomized Clinical Trial Journal Club - Zachary Klaassen
Rectal Spacing With Hyaluronic Acid for Hypofractionated Radiation Therapy for Prostate Cancer, Barrigel®, Journal Club - Zachary Klaassen
Active Surveillance as a Safe Strategy for Disease Management Among Men With Prostate Cancer: Findings From a Swedish Cohort Study, Journal Club - Zachary Klaassen
Analyzing the ARASENS Trial: Darolutamide Boosts Survival in Prostate Cancer Subgroups Journal Club - Zachary Klaassen
The Association of the Pandemic With Prostate Biopsy and Prostate Cancer Diagnosis Rates Among Black vs White Patients in the Veterans Affairs Health Care System Journal Club - Zachary Klaassen
Mediators of Racial Disparities in Prostate mpMRI Journal Club - Zachary Klaassen
The Sequencing of Short-Term ADT with Radiotherapy in Patients with Non-metastatic Prostate Cancer in the SANDSTORM Meta-Analysis, Journal Club - Zachary Klaassen
Exploratory Analysis of Pain and Health-Related Quality of Life in Patients Given Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone for mCRPC, Journal Club - Zachary Klaassen
Assessing Disparities in Receipt of Shorter Radiation Regimens and Treatment Noncompletion in Prostate Cancer, Journal Club - Zachary Klaassen
Efficacy and Safety of Darolutamide in the Planned Subgroup Analysis of the Phase 3 ARAMIS Trial, Journal Club - Zachary Klaassen
Dynamic Change in Patient-Reported Pain and its Association with PFS and Overall Survival in Men with De Novo Metastatic Castrate-Sensitive Prostate Cancer Journal Club - Zachary Klaassen
The Efficacy of ADT Plus Androgen Receptor Axis–Targeted Therapy (ARAT) with the Triplet of ADT, ARAT, and Docetaxel in mHSPC Journal Club - Zachary Klaassen
The Efficacy and Safety of Abiraterone Plus Prednisone, With or Without Radiotherapy, in Addition to Standard of Care (PEACE-1): Journal Club – Zachary Klaassen
5-Year Follow-Up Results From the STAMPEDE Randomised Trial: Abiraterone Acetate Plus Prednisolone for Metastatic Patients Starting Hormone Therapy: Journal Club – Zachary Klaassen
The Underrepresentation of Black and Hispanic Men in Clinical Trials Compared With Their Share of Prostate Cancer Incidence: Journal Club – Zachary Klaassen
Key Update on PARP Inhibitors from the NCCN Prostate Cancer Guidelines, Journal Club - Christopher Wallis & Zachary Klaassen
What Urologists Need to Know: mpMRI for the Detection of Clinically Significant Prostate Cancer Journal Club - Zachary Klaassen
SALV-ENZA Trial: Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy Journal Club - Zachary Klaassen
Treatment-Specific Out-of-Pocket Costs for Patients Undergoing Localized Prostate Cancer Journal Club - Zachary Klaassen
Differences in Mental Health Outcomes According to the Treatment Received for Men Being Treated with Localized Prostate Cancer Journal Club - Zachary Klaassen
Using MRI to Safely Prevent Unnecessary Protocol-Advised Repeat Biopsy During Active Surveillance Journal Club - Zachary Klaassen
Comparing the Relative Benefits of Radiotherapy Dose Escalation ± Short-Term or Long-Term ADT as Treatment Intensification for Localized Prostate Cancer Journal Club - Zachary Klaassen
Improvement in rPFS with Abiraterone Plus Olaparib Over Abiraterone Plus Placebo in First-Line mCRPC Irrespective of HRR Mutation Status, The PROpel Trial Journal Club - Zachary Klaassen
Sustained Benefit to Metastasis-Directed Therapy Versus Observation: A Pooled Analysis of the STOMP and ORIOLE Trials Journal Club - Zachary Klaassen
Nivolumab/Ipilimumab (Nivo/Ipi) with or Without CBM588 in Metastatic Renal Cell Carcinoma Journal Club - Zachary Klaassen
Atezolizumab as Adjuvant Therapy After Resection for Patients with Renal Cell Carcinoma with Increased Risk of Recurrence: IMmotion010 Trial, Journal Club - Zachary Klaassen
10-year Results DART 01-05, High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localized Prostate Cancer Journal Club - Zachary Klaassen
VIABLE Phase 3 Trial: Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With mCPRC, Journal Club - Christopher Wallis & Zachary Klaassen
Electronic Symptom Monitoring During Cancer Treatment for Improved Quality of Life, Journal Club - Christopher Wallis & Zachary Klaassen
223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Zachary Klaassen
Recovery and Morbidity After Robot-Assisted Radical Cystectomy With Intracorporeal Reconstruction vs Open Radical Cystectomy, the iROC Trial, Journal Club – Christopher Wallis & Zachary Klaassen
Long-Term Follow-Up Results (CheckMate 9ER) Trial, Journal Club - Christopher Wallis & Zachary Klaassen
Reducing Treatment Burden For Patients with Localized GG 2 or 3 Intermediate-Risk Prostate Cancer with MRI-Guided Focused Ultrasound Focal Therapy, Journal Club - Christopher Wallis & Zachary Klaassen
18F-DCFPyL PET/CT Detection Rates in Patients with Biochemical Recurrent Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
The Benefit of Adding Short-Term ADT to Prostate Bed Salvage Radiotherapy to Prevent Prostate Cancer Progression, The SPPORT Trial, Journal Club - Christopher Wallis & Zachary Klaassen
An Association Between Lower Facility Level PSA Screening Rates and Higher Metastatic Prostate Cancer Incidence Rates, Journal Club - Christopher Wallis & Zachary Klaassen
225Ac-PSMA-617 Post ADT in mCRPC Patients: Response to Treatment and Survival Analysis, Journal Club - Christopher Wallis & Zachary Klaassen
EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis, The PRIMARY Score - Journal Club - Christopher Wallis & Zachary Klaassen
Trends in Incidence of Metastatic Prostate Cancer in the US - Christopher Wallis & Zachary Klaassen
Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen
Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen
The Clinical Trial Protocol of UpFront PSMA, Phase 2 Study of Sequential 177Lu‐PSMA‐617 and Docetaxel vs Docetaxel in Metastatic Hormone‐naïve Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
Treatment Class-Specific Outcomes of Patients Receiving Immune Checkpoint Inhibitor vs Taxane Chemotherapy by Tumor Mutational Burden for mCRPC - Christopher Wallis & Zachary Klaassen
The Role of Screening MRI To Detect Radiologic Evidence of Spinal Cord Compression With Subsequent Pre-Emptive Treatment in Men With Metastatic Castration-Resistant Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
DNA Repair Genes Associated With Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
The Combination of PSMA + MRI vs to MRI Alone in the Diagnostic Performance for Detecting Clinically Significant Prostate Cancer (PRIMARY) - Christopher Wallis & Zachary Klaassen
Molecular Subtyping and Neoadjuvant Chemotherapy in Bladder Cancer - Christopher Wallis & Zachary Klaassen
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG the KEYNOTE-057 Study, Journal Club – Christopher Wallis & Zachary Klaassen
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
CheckMate 274 Trial of Adjuvant Nivolumab vs Placebo in Patients Who Underwent Radical Surgery for High-Risk Muscle-Invasive Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
CALGB 90601, Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma Journal Club - Christopher Wallis & Zachary Klaassen
OMNIVORE - Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
The Use of MRI With Targeted Biopsy in Prostate Cancer Screening Journal Club - Christopher Wallis & Zachary Klaassen
225Actinium PSMA-617 and 177Lutetium PSMA-617 Tandem Therapy in mCRPC Patients, Journal Club – Christopher Wallis & Zachary Klaassen
OLIGOPELVIS GETUG P07, Salvage Radiotherapy Combined With Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
The First Multiplex Gene Expression Liquid Biopsy Assay to Assess Potential ARSI Resistant Mechanisms Simultaneously In the Treatment of Metastatic Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Is There Still a Role for Cytoreductive Nephrectomy? Analysis from the CARMENA Trial, Journal Club - Christopher Wallis & Zachary Klaassen
Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic, Journal Club - Christopher Wallis & Zachary Klaassen
Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Klaassen
Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk Nonmetastatic Prostate Cancer: STAMPEDE Platform Protocol, Journal Club- Christopher Wallis & Zachary Klaassen
Efficacy and Safety of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Defects (GALAHAD) Journal Club - Christopher Wallis & Zachary Klaassen
The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
PSMA PET CT Derived Risk-Stratification Tool for High-risk Prostate Cancer - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Racial and Ethnic Disparity in the Use of Prostate MRI - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence - UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
The Addition of Docetaxel to Radiotherapy and ADT in Nonmetastatic Unfavorable-Risk Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
Sequential Radiotherapy May Facilitate Deferral of Systemic Therapy Initiation in Oligometastatic Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
Risk Factors for Bladder Recurrence After Minimally Invasive Nephroureterectomy in UTUC, Journal Club- Christopher Wallis & Zachary Klaassen
Treatment-Related Regret Among Men With Localized Prostate Cancer Journal Club - Christopher Wallis & Zachary Klaassen
The Efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC, Journal Club - Christopher Wallis & Zachary Klaassen
Variables Associated with the Use of Blue Light Cystoscopy Journal Club - Christopher Wallis & Zachary Klaassen
NCCN Guideline Review on Prostate Cancer - Epidemiology, Initial Diagnosis, and Life Expectancy of Men With Prostate Cancer: Journal Club – Christopher Wallis & Zachary Klaassen
NCCN Guidelines on Prostate Cancer Reviewing Advanced Prostate Cancer Neuroendocrine Disease, Bone and Visceral Metastases, and Treatment Sequencing – Christopher Wallis & Zachary Klaassen
NCCN Prostate Cancer Clinical Practice Guidelines on Risk Stratification for Clinically Localized Prostate Cancer – Christopher Wallis & Zachary Klaassen
Observation and Active Surveillance in the NCCN Prostate Cancer Guidelines- Christopher Wallis and Zachary Klaassen
NCCN Guidelines - Staging Evaluation and Imaging Approaches in Prostate Cancer – Christopher Wallis and Zachary Klaassen
NCCN Guidelines on Prostate Cancer Genetics - Christopher Wallis & Zachary Klaassen
NCCN Guidelines on Prostate Cancer - A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Christopher Wallis and Zachary Klaassen
NCCN Guidelines on Prostate Cancer: A Focus on Chemotherapy, Immunotherapy, and Targeted Therapy in Advanced Prostate Cancer - Chemotherapeutic Approaches - Christopher Wallis and Zachary Klaassen
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer, The VISION Trial Journal Club - Christopher Wallis & Zachary Klaassen
The Best Candidates for PSMA PET/CT as the Primary Staging Approach for High-risk Prostate Cancer - Christopher Wallis & Zachary Klaassen
Long Term Use of Lutetium-177-PSMA Therapy for Men With Metastatic Castration-Resistant Prostate Cancer, Journal Club – Christopher Wallis & Zachary Klaassen
Intermittent vs Continuous ADT for Patients A Review of the NCCN Guidelines – Christopher Wallis and Zachary Klaassen
ADT for Castration-Naive Disease A Review of the NCCN Prostate Cancer Guidelines – Christopher Wallis and Zachary Klaassen
The Cost-Effectiveness of PSMA-PET/CT When Compared with Conventional Imaging, An Analysis Informed by the proPSMA Trial - Journal Club - Christopher Wallis & Zachary Klaassen
The Role of 18F-Fluciclovine-PET/CT in Improving Cancer Control Compared With Conventional Imaging Alone for Salvage Postprostatectomy Radiotherapy, the EMPIRE-1 Trial Journal Club – Christopher Wallis & Zachary Klaassen
First-Line Immunotherapy, Targeted Therapy, and Combination Therapy Associated with Improved OS for Metastatic Clear Cell Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaass
ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma Journal Club – Christopher Wallis & Zachary Klaassen
NCCN Guidelines on Prostate Cancer: A Focus on Castration-Resistant Prostate Cancer - Christopher Wallis and Zachary Klaassen
The NCCN Guidelines on Androgen Deprivation Therapy in Localized Disease, Regional Disease, and Palliative Treatment - Christopher Wallis and Zachary Klaassen
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, The CLEAR Trial Journal Club - Christopher Wallis & Zachary Klaassen
The Pattern of Metastatic Spread Impact on Efficacy of Enzalutamide - The ARCHES Study Journal Club - Christopher Wallis & Zachary Klaassen
Talazoparib for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations (TALAPRO-1) Journal Club - Christopher Wallis & Zachary Klaassen
Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma, Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors: TROPHY-U-01 Journal Club – Christopher Wallis & Zachary Klaassen
Durvalumab Combination in Advanced Urothelial Cancer based on an Adaptive Biomarker-driven Trial Design - Christopher Wallis & Zachary Klaassen
Abiraterone Acetate Plus Prednisone in Black and White Men with Metastatic Castrate-Resistant Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
A Phase 1 Trial and Biomarker Analysis of HIF-2α in Renal Cell Carcinoma With Belzutifan (MK-6482), Journal Club – Christopher Wallis & Zachary Klaassen
Treatment Effect of 177Lu-PSMA in Low-Volume mHSPC Patients, Journal Club – Christopher Wallis & Zachary Klaassen
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
Improved Survival for Men Treated With Enzalutamide Added to Testosterone Suppression Who Present With Distant Metastases Years After Diagnosis of mHSPC Journal Club – Christopher Wallis and Zachary Klaassen
The BRAVO-Feasibility Study, Intravesical Maintenance BCG vs Radical Cystectomy in BCG-Naive Patients, A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Journal Presentation - Christopher Wallis & Zachary Klaassen
The Diagnostic Performance of PSMA PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) - Christopher Wallis & Zachary Klaassen
Practical Considerations For the Use of Switch Maintenance Therapy: Avelumab First-Line Maintenance in Locally Advanced or Metastatic Urothelial Carcinoma Journal Club - Christopher Wallis & Zachary Klaassen
Metastasis-Directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
The Decipher® Genomic Classifier for Recurrent Prostate Cancer in the NRG/RTOG 9601 Randomized Clinical Trial, Journal Club - Christopher Wallis & Zachary Klaassen
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma a UroToday Journal Club - Christopher Wallis and Zachary Klaassen
Survivorship Care Plans Addressing Long-term Mental Health Among Survivors of Testicular Cancer, Journal Club - Christopher Wallis & Zachary Klaassen
Real-World Treatment Patterns and Health Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) - Christopher Wallis and Zachary Klaassen
Stereotactic Ablative Body Radiotherapy in Patients in Oligometastatic Cancers: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Racial Disparity and Outcomes Among US Patients with Cancer and COVID-19 A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Durvalumab Vs. Chemotherapy in Previously Untreated Patients with Unresectable Metastatic Urothelial Carcinoma (DANUBE) A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Extended 4-Year Followup of CheckMate 214 Trial, Nivolumab Plus Ipilimumab for First-Line Treatment of Advanced Renal Cell Carcinoma: A UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Timing of Radiotherapy After Radical Prostatectomy (RADICALS-RT) Journal Club - Zachary Klaassen and Christopher Wallis
Imaging-Based Prostate Cancer Screening Among BRCA Mutation Carriers - A UroToday Journal Club
Rucaparib in Men with Metastatic Castration-Resistant Prostate Cancer A Journal Club on the TRITON 2 Study - Christopher Wallis & Zachary Klaassen
(TROG 08.03/ANZUP RAVES) Phase 3 Trial on Adjuvant Radiotherapy Versus Early Salvage Radiotherapy Following Radical Prostatectomy Journal Club - Christopher Wallis & Zachary Klaassen
Adjuvant or Early Salvage Radiotherapy for the Treatment of Localized and Locally Advanced Prostate Cancer - The ARTISTIC Collaborative Journal Club - Christopher Wallis ad Zachary Klaassen
First-Line Maintenance Avelumab in Patients with advanced Urothelial Carcinoma, A New Standard of Care - JAVELIN Bladder 100 Journal Club - Christopher Wallis & Zachary Klaassen
Journal Club: Discussing Quality of Life in Patients with Metastatic Prostate Cancer Following Treatment with Cabazitaxel Versus Abiraterone or Enzalutamide - Christopher Wallis & Zachary Klaassen
Significantly Longer Duration of Overall Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - PROfound Study Journal Club - Zachary Klaassen and Christopher Wallis
Journal Club on Ureteroscopic Doppler Ultrasonography: Mapping Renal Blood Flow From Within the Collecting System- Evangelos Liatsikos and Roshan Patel
Journal Club: The Efficacy and Safety of MitoGel™ (UGN-101) on Ablation of Upper Urinary Tract Urothelial Carcinoma (OLYMPUS) - Zachary Klaassen
PROSPER Trial Journal Club: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer - Zachary Klaassen and Christopher J.D. Wallis
Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen
The Impact of Treatment Delays of Upper Tract Urothelial Carcinoma (UTUC) During the COVID-19 Pandemic Journal Club - Zachary Klaassen
Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen
Journal Club: The Evaluation of Cxbladder and Adjudication of Atypical Cytology - Sia Daneshmand
Blue Light Cystoscopy for Diagnosis of Bladder Cancer - A Journal Club Review by Badrinath Konety
Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis